Gerresheimer (ETR:GXI) has been assigned a €70.00 ($81.40) target price by research analysts at Commerzbank in a research report issued to clients and investors on Thursday. The firm presently has a “neutral” rating on the stock. Commerzbank’s price target would suggest a potential upside of 13.82% from the stock’s current price.
Several other research analysts have also commented on GXI. Deutsche Bank set a €86.00 ($100.00) price target on Gerresheimer and gave the stock a “buy” rating in a research report on Monday, July 16th. DZ Bank reissued a “buy” rating on shares of Gerresheimer in a research report on Thursday, July 12th. Berenberg Bank set a €78.00 ($90.70) price target on Gerresheimer and gave the stock a “buy” rating in a research report on Tuesday, July 10th. Credit Suisse Group set a €72.00 ($83.72) price target on Gerresheimer and gave the stock a “buy” rating in a research report on Monday, July 9th. Finally, Independent Research set a €77.00 ($89.53) price target on Gerresheimer and gave the stock a “neutral” rating in a research report on Thursday, July 12th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of €71.67 ($83.33).
Shares of ETR GXI opened at €61.50 ($71.51) on Thursday. Gerresheimer has a twelve month low of €59.97 ($69.73) and a twelve month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Recommended Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.